CN104286844A - Food, health product or medicine composition capable of improving immunity - Google Patents
Food, health product or medicine composition capable of improving immunity Download PDFInfo
- Publication number
- CN104286844A CN104286844A CN201410474941.9A CN201410474941A CN104286844A CN 104286844 A CN104286844 A CN 104286844A CN 201410474941 A CN201410474941 A CN 201410474941A CN 104286844 A CN104286844 A CN 104286844A
- Authority
- CN
- China
- Prior art keywords
- food
- health products
- pharmaceutical composition
- raw material
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title claims abstract description 21
- 230000036039 immunity Effects 0.000 title claims abstract description 17
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 20
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 20
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 20
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 20
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 19
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 244000241872 Lycium chinense Species 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002803 maceration Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 244000241838 Lycium barbarum Species 0.000 abstract description 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241001633680 Polygonatum odoratum Species 0.000 abstract 1
- 241000037831 Polygonatum sibiricum Species 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 239000000047 product Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 241000208340 Araliaceae Species 0.000 description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 description 13
- 235000008434 ginseng Nutrition 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000000976 ink Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000955 splenic vein Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 2
- -1 sorbierite Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 125000000853 cresyl group Chemical class C1(=CC=C(C=C1)C)* 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a food, a health product or a medicine composition capable of improving immunity. The food, the health product or the medicine composition is prepared from the following raw materials in parts by weight: 1.5-2 parts of gardenia jasminoides ellis, 1-1.5 parts of polygonatum sibiricum, 1-1.5 parts of wolfberry fruits, 1 part of polygonatum odoratum and 0.5-1 part of dried longan pulp. According to the composition, the immunity of organisms can be effectively enhanced; the composition has accurate and proper medicine compatibility and expresses the synergistic effect; and the pharmacodynamics activity is remarkably better than that of each raw material.
Description
Technical field
The present invention relates to a kind of food, health products or the pharmaceutical composition that improve immunity.
Background technology
Immunity is the defense mechanism of human body self, is human bioequivalence and any foreign matter (virus, bacterium etc.) eliminating external intrusion; Process is old and feeble, damage, the ability of mutant cell and virus infected cell in the own cells of dead, sex change and identification and handling body.
The immunity of human body depends on gene mostly, but the impact of environment is also very large, as diet, sleep, motion, pressure etc.Wherein diet has conclusive influence power, because the composition of some food can assist stimulating immune system, strengthens immunocompetence.If lack these important nutrient compositions, the immune system function of health also can be had a strong impact on.
Summary of the invention
The object of the present invention is to provide a kind of food, health products or the pharmaceutical composition that improve immunity.
Particularly, the invention provides a kind of food, health products or the pharmaceutical composition that improve immunity, its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 1.5 ~ 2 parts, sealwort 1 ~ 1.5 part, the fruit of Chinese wolfberry 1 ~ 1.5 part, radix polygonati officinalis 1 part, arillus longan 0.5 ~ 1 part.
Further, its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 2 parts, sealwort 1 part, the fruit of Chinese wolfberry 1 part, radix polygonati officinalis 1 part, arillus longan 1 part.
Further, its raw material is made up of the component of following weight proportion:
Cape jasmine 1.5 ~ 2 parts, sealwort 1 ~ 1.5 part, the fruit of Chinese wolfberry 1 ~ 1.5 part, radix polygonati officinalis 1 part, arillus longan 0.5 ~ 1 part.
Further, its raw material is made up of the component of following weight proportion:
Cape jasmine 2 parts, sealwort 1 part, the fruit of Chinese wolfberry 1 part, radix polygonati officinalis 1 part, arillus longan 1 part.
Above-mentioned each raw material is integration of drinking and medicinal herbs material, namely can be used as medicine or health products use, also can be used as food and use.
Wherein, it be by the medicinal powder of raw material, water extract or/and ethanol extract is active component, add the oral administration formulation that pharmaceutically conventional auxiliary material or complementary composition are prepared from.
Such as, described formulation is selected from vina, oral liquid, beverage, granule, powder, pill, tablet or capsule.
Pharmaceutically acceptable auxiliary material of the present invention, refer to the material be included in addition to the active ingredient (s in formulation, include but are not limited to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, conditioning agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc.Adhesive comprises syrup, Arabic gum, gelatin, sorbierite, tragacanth, cellulose and its derivates (as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or HPMC etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivative thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate etc.), sorbierite or glycine etc.; Lubricant comprises superfine silica gel powder, dolomol, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol etc.; Disintegrant comprises starch and derivative (as sodium carboxymethyl starch, Explotab, pregelatinized starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.; Wetting agent comprises lauryl sodium sulfate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Bacteriostatic agent comprises 0.5% phenol, 0.3% cresols, 0.5% anesin etc.; Conditioning agent comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer (comprising sodium dihydrogen phosphate and sodium hydrogen phosphate) etc.; Emulsifier package is smooth containing Tween-80, aliphatic acid sorb, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.; Solubilizer comprises Tween-80, bile, glycerine etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-claimed cpd or the leading position of derivative in treatment of diseases, and only play auxiliary effect, these auxiliary effects are only the utilizations to this composition known activity, are the usual adjuvant treatment modality of field of medicaments.If by above-mentioned complementary composition and the compounds of this invention with the use of, still should belong to the scope of protection of the invention.
Present invention also offers the preparation method of above-mentioned food, health products or pharmaceutical composition, it is characterized in that:
(1) raw material is taken by proportioning;
(2) by raw material with wine Soakage extraction, get maceration extract, preparation formulation.
Further, described wine is bent wine.
Further, the described bent wine number of degrees are 40 ~ 55 degree.In the present invention's detailed description of the invention, the bent wine number of degrees of use are 45 degree.
Water extract or be used as medicine with medicinal powder is all Chinese medicine tradition occupation modes, and after water extraction, because the soluble end of water is wide, can, by most of active ingredient stripping, medicine is more easily absorbed by the body, onset be faster, the form of medication such as such as decoction; Be used as medicine with former powder, the surface area of medicinal powder is larger, also active ingredient absorption in vivo in medicinal material is conducive to, but medicinal material un-extracted, active ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is comparatively slow, but also weakens the toxicity that in medicinal material, harmful components cause human body simultaneously, be suitable for long-term taking, as former powder is prepared into the form of medication such as pill.At present in pharmacy procedure, ethanol extracts medicine as solvent, also be one of the most common extracting mode, ethanol is semi-polarity solvent, solubility property circle is between polarity and non-polar solven, some composition water miscible can be dissolved, also some compositions that non-polar solven dissolves can be dissolved, usually decocting is replaced with alcohol extract, thus avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of active ingredient, but comparatively water is expensive for the price of ethanol, in the large production of modern pharmaceutical industry, in order to save production cost, usually still based on decocting.When the wine dipper thing of known compositions of the present invention has physiologically active, demand during in order to adapt to various production and use, optionally water extraction, former powder, alcohol extracting or their combined method can prepare concrete formulation.
Present invention also offers above-mentioned food, health products or pharmaceutical composition and prepare the purposes in food, health products or the medicine improving immunity.
Research shows, the present composition effectively can strengthen immunity of organisms, and present composition compatibility is precise and appropriate, has played synergy, and drug activity is obviously better than each single raw material.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
Below by way of the form of specific embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The preparation of embodiment 1 present composition
Get cape jasmine 20g, sealwort 10g, fruit of Chinese wolfberry 10g, radix polygonati officinalis 10g, arillus longan 10g.After pulverizing, with 45 write music wine soak, obtain vina of the present invention.
The preparation of embodiment 2 present composition
Get cape jasmine 20g, sealwort 10g, fruit of Chinese wolfberry 10g, radix polygonati officinalis 10g, arillus longan 10g, add water 60 DEG C of temperature leachings 3 times, merge leachate, filter, concentrated, add appropriate filler, be prepared into buccal tablet.
The preparation of embodiment 3 present composition
Get cape jasmine 20g, sealwort 10g, fruit of Chinese wolfberry 10g, radix polygonati officinalis 10g, arillus longan 10g, add water 60 DEG C of ultrasonic extractions 3 times, merge extract, filter, concentrated, add appropriate flavouring, be prepared into beverage.Beneficial effect of the present invention is illustrated below by way of test example.
Test example 1 present composition efficacy test
1. optimum proportioning screening
1.1 experiment material
1.1.1 experimental drug
Test sample: cape jasmine, sealwort, the fruit of Chinese wolfberry, radix polygonati officinalis, arillus longan, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Positive reference substance: ginseng, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Negative controls: the bent wine of Luzhou Old Cellar two, 45 degree, purchased from reciprocal supermarket.
For determining optimum proportioning dosage, setting various dose proportioning group carries out Preliminary screening, is respectively:
Proportioning group 1 (cape jasmine: sealwort: the fruit of Chinese wolfberry: radix polygonati officinalis: arillus longan=2:1:1:1:1);
Proportioning group 2 (cape jasmine: sealwort: the fruit of Chinese wolfberry: radix polygonati officinalis: arillus longan=2:1.5:1:1:0.5);
Proportioning group 3 (cape jasmine: sealwort: the fruit of Chinese wolfberry: radix polygonati officinalis: arillus longan=2:1:1.5:1:0.5);
Proportioning group 4 (cape jasmine: sealwort: the fruit of Chinese wolfberry: radix polygonati officinalis: arillus longan=1.5:1:1.5:1:1).
Add respectively 45 write music wine soak for 100g crude drug in whole/100ml medicinal extract for subsequent use.
1.1.2 experiment reagent and instrument
752 ultraviolet specrophotometers, constant water bath box, centrifuge etc.
1.1.3 animal used as test
BALB/c mouse, Da Shuo bio tech ltd, Chengdu provides, and body weight 18-22g is female, the animal quality certification number: animal credit number: SCXK (river) 2008-24.
1.2 experimental technique
1.2.1 immune organ weight and organ index
Get 100 mouse and be divided into 10 groups at random, blank group (equal-volume 45 write music wine), ginseng group (5gkg
-1), proportioning group 1 (10gkg
-1), proportioning group 2 (10gkg
-1), proportioning group 3 (10gkg
-1), proportioning group 4 (10gkg
-1).After 10d gavage, give each group of mouse tail vein injection india ink (4 times of dilutions) 0.1ml/10g in order.Every mouse all after injection prepared Chinese ink 2min and 10min punctual respectively in adjoin blood sampling 20 μ l, and survey rapidly absorbance (A).Get Mouse Liver simultaneously, spleen is weighed, by formulae discovery phagocytic index (α).Each dosage group result compares with solvent control group carries out variance analysis.
1.3 experimental result
Experimental result is shown in Table 1:
Table 1 is on the impact of mouse carbonic clearance
Note: compare with blank group, * P < 0.05, * * P < 0.01
From table 1, compared with blank group, ginseng group, proportioning 1,4 groups of mouse carbonic clearance phagocytic index increase (P<0.05, P < 0.01), and other each group trend only with increase, and no difference of science of statistics (P>0.05).
To sum up test, proportioning group 1 increases carbonic clearance phagocytic index best results, has and strengthens immunization significantly, therefore proportioning group 1 (cape jasmine: sealwort: the fruit of Chinese wolfberry: radix polygonati officinalis: arillus longan=2:1:1:1:1) is optimum dose proportion.
2. the drug effect of the present composition and simple contrasts
2.1 experiment material
2.1.1 experimental drug
Test sample: cape jasmine, sealwort, the fruit of Chinese wolfberry, radix polygonati officinalis, arillus longan, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Positive reference substance: ginseng, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Negative controls: the bent wine of Luzhou Old Cellar two, 45 degree, purchased from reciprocal supermarket.During test the high, medium and low dosage of compound add 45 write music wine to soak be 200,100,50g crude drug in whole/100ml medicinal extract is for subsequent use, each single medicine preparation is that 50g crude drug in whole/100ml medicinal extract is for subsequent use with method.
2.1.2 experiment reagent and instrument
96 well culture plates, CO2 incubator, 752 ultraviolet specrophotometers, ELIASA, constant water bath box, centrifuge, Microhemagglutination brassboard, microscope, RPMI1640 cell culture fluid, calf serum, concanavalin A (ConA), MTT, Hanks liquid, PBS buffer solution (pH value 7.2-7.4)), DNF (DNFB), sheep red blood cell (SRBC) (SRBC), complement (GPS), SA buffer solution, india ink, Giemsa dye liquor, YAC-1 cell etc.
2.1.3 animal used as test
BALB/c mouse, Da Shuo bio tech ltd, Chengdu provides, and body weight 18-22g is female, the animal quality certification number: animal credit number: SCXK (river) 2008-24
2.2 experimental technique
2.2.1 immune organ weight and organ index
Get 100 mouse and be divided into 10 groups at random, blank group (equal-volume 45 write music wine), ginseng group (5gkg
-1), compound high dose group (20gkg
-1), dosage group (10gkg in compound
-1), compound low dose group (5gkg
-1), cape jasmine group (10gkg
-1), sealwort group (10gkg
-1), matrimony vine subgroup (10gkg
-1), radix polygonati officinalis (10gkg
-1), arillus longan group (10gkg
-1), after 10d gavage, femoral artery sacrificed by exsanguination, the spleen, the thymus gland that take out animal are weighed, and are calculated organ index.
Administration volume: 10ml/kg.
Administration frequency and cycle: 1 times/day, totally 10 days.
Organ index (%)=organ weights (g)/the weight of animals (g) * 100%
2.2.2 mouse delayed allergy (DTH) measures
Administration and grouping, with 2.1, in gavage 6d, are injected 2% sheep red blood cell (SRBC) (SRBC) 0.2ml/ to mouse peritoneal and are only carried out sensitization, and after immunity, the left back sufficient sole of the foot portion hypodermic injection 20%SRBC of the every mouse of 4d (20 μ l/ only) attacks.And 24h measures the same part thickness of the left back sufficient sole of the foot of every mouse before attack and after attacking, calculate and attack forward and backward difference, each dosage group result compares with solvent control group carries out variance analysis.
2.2.3ConA inducing mouse Splenic vein hemodynamics experiment (mtt assay)
Administration and grouping are with 2.1, and get spleen, splenocyte suspension processed to each group of mouse is aseptic, adjusting splenocyte concentration with RPMI1640 complete culture solution is 3*10
9individual/L, carries out lymphproliferation response according to mtt assay in program, finally surveys its absorbance (A) at 752 ultraviolet-uisible spectrophotometer 570nm wavelength places, calculates ConA
+with ConA
-the absorbance in each hole.Each dosage group result compares with blank group carries out variance analysis.
2.2.4 serum hemolysin measures
Administration and grouping are with 2.1, and inject 2%SRBC (0.2ml/ only) in gavage 10d to mouse peritoneal, after immunity, 5d plucks eyeball blood sampling, separation of serum at the clear hemolysin test of the enterprising promoting circulation of blood of Microhemagglutination plate, hatch 3h for 37 DEG C, statistics hemagglutination degree, calculates corresponding antibodies product.Each dosage group result compares with blank group carries out variance analysis.
2.2.5 antibody-producting cell (PFC) detects
Administration and grouping are with 2.1, and in gavage 10d to mouse peritoneal injection 2%SRBC0.2mL/ only, after immunity, 5d puts to death, and solution takes spleen and prepares splenocyte suspension, are 5*10 by RPMI1640 complete culture solution adjustment splenocyte concentration
9individual/L.Follow procedure method prepares agarose slide, at CO
2incubator (37 DEG C, 5%CO
2) in add complement after incubation 1.5h, then incubation 1.5h, counting often opens the hemolysis plaque number that thin agar layer slide is formed.Each dosage group result compares with solvent control group carries out variance analysis.
2.2.6 mouse carbonic clearance is tested
Administration and grouping, with 2.1, give each group of mouse tail vein injection india ink (4 times of dilutions) 0.1ml/10g in order.Every mouse all after injection prepared Chinese ink 2min and 10min punctual respectively in adjoin blood sampling 20 μ l, and survey rapidly absorbance (A).Get Mouse Liver simultaneously, spleen is weighed, by formulae discovery phagocytic index (α).Each dosage group result compares with solvent control group carries out variance analysis.
2.2.7 Turnover of Mouse Peritoneal Macrophages engulfs chicken red blood cell experiment
Administration and grouping are with 2.1, and after last gives tested material, each group mouse peritoneal only injects 20% chicken erythrocyte suspension 1ml/, and interval 30min puts to death mouse, Intraperitoneal injection physiological saline 2ml/ only, abdominal cavity washing lotion film-making is got, 37 DEG C of incubation 30min, rinsing, fixing poststaining microscopy after jolting 1min.Counting engulfs the red macrophage number of chicken and macrophage phagocytic chicken red blood cell number, to compare carry out variance analysis with each dosage group phagocytic rate conversion value and phagocytic index with solvent control group.
2.2.8NK cytoactive detection (LDH determination method)
Mouse cervical dislocation is put to death, asepticly gets spleen, make splenocyte suspension 2*10
7individual/ml, get the well-grown YAC-1 cell of 24h after going down to posterity, this is target cell, gets target cell 4*10
5individual/ml and each 100 μ l of effector cell (effect target is than 50:1), add in U-shaped 96 well culture plates, target cell Spontaneous release hole adds target cell and each 100 μ l of nutrient solution, and the maximum release aperture of target cell adds target cell and each 100 μ l of 1%NP40.Above-mentionedly everyly respectively establish 3 parallel holes, put CO
2incubator incubator (5%CO
2, 37 DEG C) in cultivate 4h.Then by 96 well culture plates with the centrifugal 5min of 1500r/min, every hole is drawn in 96 well culture plates at the bottom of supernatant 100 μ l horizontalization, add LDH matrix liquid 100 μ l simultaneously, react 8 minutes, every hole adds the HCL30 μ l of lmol/L, measure optical density (OD) value at ELIASA 490nm place, calculate NK cytoactive.
2.3 experimental result
2.3.1 immune organ weight and organ index
Experimental result is as shown in table 2:
Table 2 on the impact of mouse immune organ weight and organ index (
n=10)
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 2, compared with blank group, the each group of thymus index no significant difference (P>0.05) to mouse, the index and spleen index of high dose group mouse significantly increases (P<0.01), ginseng, in, low dose group mouse spleen index increase (P<0.05).
2.3.2 mouse delayed allergy (DTH) measures
Experimental result is as shown in table 3:
Table 3 is on the impact of mouse delayed allergy (DTH)
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 3, after attacking with SRBS, compared with blank group, ginseng group, high, medium and low dosage group have the effect (P<0.05, P<0.01) increasing mouse foot sole of the foot thickness.
2.3.3ConA inducing mouse Splenic vein hemodynamics experiment (mtt assay)
Experimental result is as shown in table 4:
The impact that table 4 is tested ConA inducing mouse Splenic vein hemodynamics
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 4, compared with blank group, high, the middle dosage group of ginseng, this product has significant difference (P<0.05), and other respectively organize equal no significant difference (P>0.05).Illustrate that the present composition can promote ConA inducing mouse Splenic vein hemodynamics.
2.3.4 serum hemolysin measures
Experimental result is as shown in table 5:
Table 5 is on the impact of mice serum hemolysin
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 5, compared with blank group, high, medium and low group of ginseng group, this product has the effect (P<0.05, P<0.01) increasing antibody product.
2.3.5 antibody-producting cell (PFC) detects
Experimental result is as shown in table 6:
Table 6 is on the impact of mouse antibodies cellulation
Note: compare with blank group, * P < 0.05, * * P < 0.01
From table 6, compared with blank group, the high, medium and low dosage group of ginseng group, this product all has the effect (P<0.05) increasing splenocyte hemolysis plaque number, and the trend (P>0.05) that all the other each group only has an increase.
2.3.6 mouse carbonic clearance is tested
Experimental result is shown in Table 7:
Table 7 is on the impact of mouse carbonic clearance
Note: compare with blank group, * P < 0.05, * * P < 0.01
From table 7, compared with blank group, ginseng group, this product high, middle dosage group mouse carbonic clearance phagocytic index increases (P<0.05), and the trend that other each group only has an increase, and no difference of science of statistics (P>0.05).
2.3.7 Turnover of Mouse Peritoneal Macrophages engulfs chicken red blood cell experiment
Experimental result is shown in Table 8:
Table 8 engulfs the impact of chicken red blood cell to Turnover of Mouse Peritoneal Macrophages
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 8, compared with blank group, ginseng group, this product high, medium and low dosage group mouse can increase the effect (P<0.05, P<0.01) of peritoneal macrophage being engulfed to chicken red blood cell.
2.3.8NK cytoactive detection
Experimental result is shown in Table 9:
Table 9 is on the impact of NK cells in mice activity
Note: compare with blank group, * P < 0.05, * * P < 0.01
As shown in Table 9, compared with blank group, the high, medium and low dosage group of ginseng group, this product has the effect (P<0.05) increasing NK cytoactive.
From the above results, the present composition is obviously better than wherein each taste medicine and is used alone, and illustrates that each component of the present composition has the effect of Synergistic.
To sum up, the present composition can significantly improve the indices of immunity, illustrates that the present composition has raising immunity of organisms, strengthens body to the effect of the defence capability of disease.
Claims (10)
1. improve the food of immunity, health products or a pharmaceutical composition, it is characterized in that: its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 1.5 ~ 2 parts, sealwort 1 ~ 1.5 part, the fruit of Chinese wolfberry 1 ~ 1.5 part, radix polygonati officinalis 1 part, arillus longan 0.5 ~ 1 part.
2. food according to claim 1, health products or pharmaceutical composition, is characterized in that: its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 2 parts, sealwort 1 part, the fruit of Chinese wolfberry 1 part, radix polygonati officinalis 1 part, arillus longan 1 part.
3. food according to claim 1, health products or pharmaceutical composition, is characterized in that: its raw material is made up of the component of following weight proportion:
Cape jasmine 1.5 ~ 2 parts, sealwort 1 ~ 1.5 part, the fruit of Chinese wolfberry 1 ~ 1.5 part, radix polygonati officinalis 1 part, arillus longan 0.5 ~ 1 part.
4. food according to claim 3, health products or pharmaceutical composition, is characterized in that: its raw material is made up of the component of following weight proportion:
Cape jasmine 2 parts, sealwort 1 part, the fruit of Chinese wolfberry 1 part, radix polygonati officinalis 1 part, arillus longan 1 part.
5. the food according to Claims 1 to 4 any one, health products or pharmaceutical composition, it is characterized in that: it be by the medicinal powder of raw material, water extract or/and ethanol extract is active component, add the oral administration formulation that pharmaceutically conventional auxiliary material or complementary composition are prepared from.
6. food according to claim 5, health products or pharmaceutical composition, is characterized in that: described formulation is selected from vina, oral liquid, beverage, granule, powder, pill, tablet, medicinal tea or capsule.
7. the preparation method of food, health products or pharmaceutical composition described in claim 1 ~ 6 any one, is characterized in that:
(1) raw material is taken by proportioning;
(2) by raw material with wine Soakage extraction, get maceration extract, preparation formulation.
8. preparation method according to claim 7, is characterized in that: described wine is bent wine.
9. preparation method according to claim 8, is characterized in that: the described bent wine number of degrees are 40 ~ 55 degree.
10. food, health products or pharmaceutical composition described in claim 1 ~ 6 any one improve the purposes in immune food, health products or medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410474941.9A CN104286844B (en) | 2014-09-16 | 2014-09-16 | A kind of improve the food of immunity, health product or pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410474941.9A CN104286844B (en) | 2014-09-16 | 2014-09-16 | A kind of improve the food of immunity, health product or pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104286844A true CN104286844A (en) | 2015-01-21 |
| CN104286844B CN104286844B (en) | 2016-09-21 |
Family
ID=52307013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410474941.9A Active CN104286844B (en) | 2014-09-16 | 2014-09-16 | A kind of improve the food of immunity, health product or pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104286844B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387560A (en) * | 2016-08-27 | 2017-02-15 | 桂林七星粉业有限责任公司 | Processing technology of hippophae rhamnoides health-care beverage capable of enhancing immunity |
| CN106954730A (en) * | 2017-02-13 | 2017-07-18 | 浙江海洋大学 | A kind of high-nutrition food for strengthening immunologic function and preparation method thereof |
| CN113413445A (en) * | 2021-06-28 | 2021-09-21 | 金牛区翔劲一类医疗器械经营部 | Composition and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197338A1 (en) * | 2000-06-06 | 2002-12-26 | Tseng Albert Peng Sheng | Botanical composition and methods for the treatment or prevention of obesity |
| CN101890130A (en) * | 2010-07-30 | 2010-11-24 | 广州白云山和记黄埔中药有限公司 | Health wine raw materials and health wine |
| CN102517189A (en) * | 2011-12-16 | 2012-06-27 | 扬子江药业集团四川海蓉药业有限公司 | Chinese medicinal health-care white spirit with health maintenance effect and preparation method thereof |
| CN102871120A (en) * | 2012-09-10 | 2013-01-16 | 三普药业股份有限公司 | Heath-care food for improving human immunity and preparation method thereof |
| CN103992924A (en) * | 2014-06-04 | 2014-08-20 | 邵阳市金台酒厂 | Health-care juice wine for enhancing body immunity and manufacturing method thereof |
-
2014
- 2014-09-16 CN CN201410474941.9A patent/CN104286844B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197338A1 (en) * | 2000-06-06 | 2002-12-26 | Tseng Albert Peng Sheng | Botanical composition and methods for the treatment or prevention of obesity |
| CN101890130A (en) * | 2010-07-30 | 2010-11-24 | 广州白云山和记黄埔中药有限公司 | Health wine raw materials and health wine |
| CN102517189A (en) * | 2011-12-16 | 2012-06-27 | 扬子江药业集团四川海蓉药业有限公司 | Chinese medicinal health-care white spirit with health maintenance effect and preparation method thereof |
| CN102871120A (en) * | 2012-09-10 | 2013-01-16 | 三普药业股份有限公司 | Heath-care food for improving human immunity and preparation method thereof |
| CN103992924A (en) * | 2014-06-04 | 2014-08-20 | 邵阳市金台酒厂 | Health-care juice wine for enhancing body immunity and manufacturing method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387560A (en) * | 2016-08-27 | 2017-02-15 | 桂林七星粉业有限责任公司 | Processing technology of hippophae rhamnoides health-care beverage capable of enhancing immunity |
| CN106954730A (en) * | 2017-02-13 | 2017-07-18 | 浙江海洋大学 | A kind of high-nutrition food for strengthening immunologic function and preparation method thereof |
| CN113413445A (en) * | 2021-06-28 | 2021-09-21 | 金牛区翔劲一类医疗器械经营部 | Composition and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104286844B (en) | 2016-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083535A (en) | Dark tea composition and application in weight losing field | |
| CN106236801A (en) | Pseudo-ginseng activity medicine that super-micro wall-broken crushing technology is made and health product and preparation method thereof | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN105338993A (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
| CN104286844B (en) | A kind of improve the food of immunity, health product or pharmaceutical composition | |
| CN103520318B (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN104758331A (en) | Chinese medicine composition capable of enhancing immunity and preparation method thereof | |
| CN106822622A (en) | A kind of relieving alcoholism and protecting liver Orally administered composition and preparation method thereof | |
| CN108210547A (en) | The preparation method and its preparation of a kind of Extracts from Leaves of Phyllanthus emblica L and anti-Ai Yingyong | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN105362337B (en) | A kind of Chinese medicine composition with heat-clearing dissipating bind function, preparation and preparation method thereof | |
| TW201221133A (en) | A medical compositions for inhibition of influenza Hemagglutinin and process for the preparation thereof | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN107753630A (en) | The pharmaceutical composition and preparation method of a kind for the treatment of of insomnia patients | |
| CN102641342B (en) | A kind of Chinese medicine extract and preparation method for the treatment of nephropathy | |
| CN101785816B (en) | Grass-leaved sweetflag extract, medicine composition with grass-leaved sweetflag extract, preparation method and application thereof | |
| CN106138164A (en) | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function | |
| CN104771595B (en) | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof | |
| CN107854609A (en) | Red ginseng, the tuber of dwarf lilyturf, fruit of Chinese magnoliavine composition are used for the purposes for preparing the medicine for the treatment of depression | |
| CN103830374A (en) | Application of three-leaf glycolipid-removal medicine in hyperuricemia | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN103082286B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN104273527B (en) | A kind of health composition and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |